Targeted Nanoparticles Boost Arsenic’s Anticancer Punch

Jul 22, 2009

Arsenic trioxide has a long history as a potent human poison, but it also has proven valuable as one of the primary treatment options for acute promyelocytic leukemia. Efforts to use arsenic trioxide to treat other types of cancer are under way, but clinical trials are revealing that the extreme toxicity of this material is likely to limit its utility as a broad-spectrum anticancer agent.

A new report appearing in the journal Molecular Cancer Therapeutics suggests that targeted nanoparticles may be able to overcome the dose-limiting toxicities of arsenic trioxide while simultaneously boosting this chemical’s anticancer activity. This work was led by Thomas O’Halloran, Ph.D., an investigator with the for Cancer Diagnostics and Therapeutics Center for Cancer Nanotechnology Excellence based at Northwestern University.

Although several research teams have prepared nanoparticulate formulations of arsenic trioxide, these efforts have been plagued by the ability of arsenic trioxide to leak rapidly out of the nanoparticles. Dr. O’Halloran and his colleagues appear to have solved this problem by encapsulating arsenic trioxide along with nickel ions within a lipid-based nanoparticle coated with poly(ethylene glycol). The resulting nanoparticles retain their arsenic trioxide payload and are stable at refrigerator temperatures for more than 6 months. In addition, the composition of the nanoparticle makes them unstable when subjected to the slightly acidic conditions found inside tumor cells. As a result, the nanoparticles fall apart and release arsenic trioxide only after being taken up by .

To further improve the therapeutic characteristics of nanoparticle-encapsulated arsenic, the investigators added a small amount of folic acid to the nanoparticle’s outer layer. Folic acid binds to a high-affinity folic acid receptor that is found on many types of tumors. Using several experimental methods, the researchers demonstrated that folate-targeted are efficiently taken up by but are ignored by other types of cells. The researchers also showed that nanoparticle-encapsulated arsenic trioxide is far more toxic to than is the drug by itself and that the coencapsulated nickel ions further increase the potency of nanoparticulate arsenic trioxide.

This work, which is detailed in the paper “Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide,” was supported by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. Investigators from Purdue University also participated in this study. An abstract is available at the journal's Web site.

Source: National Cancer Institute (news : web)

Explore further: A new imaging approach for monitoring cell metabolism

add to favorites email to friend print save as pdf

Related Stories

Pack 'Em In -- Gold Nanoparticles Improve Gene Regulation

Feb 23, 2009

Investigators at Northwestern University have found that packing small interfering RNA (siRNA) molecules onto the surface of a gold nanoparticle can protect siRNAs from degradation and increase their ability to regulate genes ...

Water-stingy agriculture reduces arsenic in rice markedly

Jul 28, 2008

A new farming method first developed to conserve precious irrigation water may have the added benefit of producing rice containing much less arsenic than rice grown using traditional rice-farming methods, researchers in the ...

Nanoparticles Overcome Anticancer Drug Resistance

Jun 12, 2006

Too often, chemotherapy fails to cure cancer because some tumor cells develop resistance to multiple anticancer drugs. In most cases, resistance develops when cancer cells begin expressing a protein, known as p-glycoprotein, ...

Polymer Nanoparticle Kills Tumors

Jan 12, 2006

Photodynamic therapy (PDT), which uses a light-sensitive chemical known as a photosensitizer to produce cell-killing “reactive oxygen,” has become an important option for the treatment of esophageal cancer and non-small ...

Recommended for you

Tuning light to kill deep cancer tumors

Oct 15, 2014

An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set ...

User comments : 0